Lung cancer is a malignant tumor that originated in the lungs and may spread to lymph nodes or other surrounding organs in the body. It can be categorized into two main types:
Non-Small Cell Lung Carcinoma (NSCLC)
Small Cell Lung Carcinoma (SCLC)
Lung cancer
The 2nd common cancer worldwide
Leading cause of cancer-related mortalities worldwide
Commonly diagnosed at advanced stages with limited treatment options
Osimertinib
The current first-line treatment used to treat patients with advanced-stage NSCLC.
Third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
Specified for NSCLC patients with EGFR T790M mutation.
Osimertinib Resistance Inevitably Develops Among NSCLC Patients
Osimertinib resistance
Develops in EGFR T790M mutation-positive NSCLC patients
Osimertinib is no longer able to halt the growth of NSCLC tumor
Nonetheless, the story doesn’t conclude here!
We, PolYneer, are committed to developing a novel bispecific antibody using a synthetic biology approach to address the unmet clinical need for new agent to overcome Osimertinib resistance in NSCLC patients.
Polyneerab
Primary binding site:
Targeting c-MET
Secondary binding site:
Their hands are made by cyclic peptides targeting EGFR
Traditional bispecific antibody production (e.g. amivantamab) relies on the co-culture of two different cell types expressing half of the light-heavy chain of the antibody, and the subsequent dimerization of the half antibody secreted by the two cell types.
Due to the complicated production process:
The therapy cost of traditional bispecific antibody is very high
Ranging from USD 30,000 to USD 170,000 per treatment, which is barely affordable to most patients
Advantages of Polyneerab
Flexible design
Lower production cost
Rapid production
More stable structure and intact Fab conformation as no protein refolding is involved
With Polyneerab in combination with Osimertinib, we believe that we can give renewed hope to NSCLC patients!!
To learn more details about our project, you can visit our specific pages
